Menu
19/07/2004
Gates Foundation donates $16m to UN malaria research
With malaria causing an estimated one million deaths and a further half billion clinical cases every year among African children, a UN-backed consortium has received $16 million in grants from the Bill & Melinda Gates Foundation to help control the disease in infants.
Announcing the grant today, the Intermittent Preventive Treatment in Infants (IPTi) Consortium said it would conduct five studies in Africa using existing antimalarial drugs to protect infants from the worst effects of the disease.
Under this approach, infants receive an antimalarial drug three times during their first year at the time of routine immunization, whether or not they have malaria. Two studies in Tanzania have shown that IPTi reduces malaria and anemia in the first year by up to 60%.
The Consortium, an alliance of the UN World Health Organization (WHO), the UN Children's Fund (UNICEF), and leading research centres in Africa, Europe and the US, hopes to quickly resolve outstanding scientific questions to allow widespread use of IPTi in Africa, with sufficient data in hand by early 2006 for a policy recommendation.
IPTi has the potential to become a major tool for malaria control because it can be given at the time of routine vaccinations delivered through the Expanded Programme on Immunization (EPI), one of the best-functioning systems of regular health contact with young children in Africa.
Because of increasing resistance in parts of Africa to the current standard antimalarial drug sulphadoxine/pyrimethamine, two trials – in Kenya and northern Tanzania – are testing different combinations of drugs.
Research in southern Tanzania addresses implementation issues that must be resolved before IPTi can be introduced on a large scale as a routine health intervention. WHO will assess whether IPTi has any effect on an infant's immune response to EPI vaccines.
By the end of 2008, the Consortium will have generated additional information on the choice of an antimalarial drug, the relationship between IPTi and the development of drug resistance, the impact of IPTi on the development of malarial immunity, and an assessment of cost-effectiveness, acceptability, mortality impact and community effectiveness.
(gmcg)
Announcing the grant today, the Intermittent Preventive Treatment in Infants (IPTi) Consortium said it would conduct five studies in Africa using existing antimalarial drugs to protect infants from the worst effects of the disease.
Under this approach, infants receive an antimalarial drug three times during their first year at the time of routine immunization, whether or not they have malaria. Two studies in Tanzania have shown that IPTi reduces malaria and anemia in the first year by up to 60%.
The Consortium, an alliance of the UN World Health Organization (WHO), the UN Children's Fund (UNICEF), and leading research centres in Africa, Europe and the US, hopes to quickly resolve outstanding scientific questions to allow widespread use of IPTi in Africa, with sufficient data in hand by early 2006 for a policy recommendation.
IPTi has the potential to become a major tool for malaria control because it can be given at the time of routine vaccinations delivered through the Expanded Programme on Immunization (EPI), one of the best-functioning systems of regular health contact with young children in Africa.
Because of increasing resistance in parts of Africa to the current standard antimalarial drug sulphadoxine/pyrimethamine, two trials – in Kenya and northern Tanzania – are testing different combinations of drugs.
Research in southern Tanzania addresses implementation issues that must be resolved before IPTi can be introduced on a large scale as a routine health intervention. WHO will assess whether IPTi has any effect on an infant's immune response to EPI vaccines.
By the end of 2008, the Consortium will have generated additional information on the choice of an antimalarial drug, the relationship between IPTi and the development of drug resistance, the impact of IPTi on the development of malarial immunity, and an assessment of cost-effectiveness, acceptability, mortality impact and community effectiveness.
(gmcg)
Related UK National News Stories
Click here for the latest headlines.
07 September 2009
Brixton Drug Gang Get Long Sentences
A gang of criminals who ran a lucrative drug dealing network from a car tyre shop in Brixton were sentenced last week to a total of 81 years in prison. Nine men, who were previously convicted of conspiracy to supply class A drugs, appeared at Kingston Crown Court today to hear their sentences.
Brixton Drug Gang Get Long Sentences
A gang of criminals who ran a lucrative drug dealing network from a car tyre shop in Brixton were sentenced last week to a total of 81 years in prison. Nine men, who were previously convicted of conspiracy to supply class A drugs, appeared at Kingston Crown Court today to hear their sentences.
22 September 2003
Billionaire gives $168m to combat malaria
The Bill & Melinda Gates Foundation today announced three grants totaling $168 million to fight malaria – a disease that, due to increased drug resistance, is on the rise in Africa for the first time in 20 years, killing more than one million people annually.
Billionaire gives $168m to combat malaria
The Bill & Melinda Gates Foundation today announced three grants totaling $168 million to fight malaria – a disease that, due to increased drug resistance, is on the rise in Africa for the first time in 20 years, killing more than one million people annually.
04 July 2008
Malaria Deaths 'Risen By Over A Third'
Deaths from malaria have risen by over a third in the past 20 years, according to figures released today.
Malaria Deaths 'Risen By Over A Third'
Deaths from malaria have risen by over a third in the past 20 years, according to figures released today.
28 May 2014
GSK To Be Investigated By SFO Over Bribery
British drugs giant GlaxoSmithKline (GSK) has confirmed that a formal criminal investigation has been launched by Britain's Serious Fraud Office (SFO) over alleged bribery in its business practices.
GSK To Be Investigated By SFO Over Bribery
British drugs giant GlaxoSmithKline (GSK) has confirmed that a formal criminal investigation has been launched by Britain's Serious Fraud Office (SFO) over alleged bribery in its business practices.
26 July 2013
Business Man Convicted Of Selling Fake Bomb Detectors
A 47-year-old man has been convicted of fraud in relation to the making and selling of fake bomb detectors. Gary Bolton, of Redshank Road in Chatham, Kent, made "nothing more than boxes with handles and antennae", which were then sold for £10,000 each, the Old Bailey heard.
Business Man Convicted Of Selling Fake Bomb Detectors
A 47-year-old man has been convicted of fraud in relation to the making and selling of fake bomb detectors. Gary Bolton, of Redshank Road in Chatham, Kent, made "nothing more than boxes with handles and antennae", which were then sold for £10,000 each, the Old Bailey heard.
-
Northern Ireland WeatherThis Evening and Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
